Researchers block cancer-related genes with small interfering peptides

February 19, 2014 by Anke Van Eekelen
Human breast cancer cells dividing. Credit: Dr David Becker, Wellcome Images

Synthetic peptides are showing promise in their ability to prevent out of control tumour growth—and according to researchers are fast becoming the core of new therapeutic opportunities for cancer treatment.

Researchers are engineering small interfering peptides (ipeps) to block the function of cancer-related genes to disrupt intracellular processes in .

This strategy targets epigenetic mutations or biological alterations, which are dynamic chemical changes in the DNA structure at the position of tumour genes.

IPeps are designed to reverse the epigenetic state of cancer cells back to normal.

Their effectiveness in was recently shown in Oncogene by Dr Pilar Blancafort, head of the Cancer Epigenetics Group at UWA, and her collaborators at the University of North Carolina at Chapel Hill, USA.

The researchers showed that a new type of synthetic iPeps – designed to target transcription factor Engrailed 1 (EN1) in triple negative cells – could modify the epigenetic status of the EN1 gene.

EN1-iPeps blocked the expression of this transcription factor in experimental tumor cells in a dish. The absence of EN-1 then activated those intracellular processes that allow normal cells to die. As a result, it stopped the uncontrollable growth.

"We hit a transcription factor that really should not have been there," Dr Blancafort says. EN1 is a brain-specific factor, normally not expressed in breast tissue.

EN1 expression contributes to the stem cell-like profile of the triple negative , known for their DNA instability and rapidly acquired resistance to chemotherapy—currently the only treatment option.

"Many people understand that cancer has a genetic base, meaning that mutations are driving cancer, but there is now also mounting evidence that the microenvironment of a tumour can modulate its outcome," Dr Blancafort says.

Epigenetic changes in cancer cells, like the level of methylation of specific DNA sites, tend to be reversible. Dr Blancafort says such changes should be seen as new targets for intervention.

She says cancers with poor clinical outcome may benefit most from combining iPeps use with conventional chemotherapy.

This way, the modifying effect of iPeps on the epigenetic profile of the cancer could prevent drug resistance and possibly 'oncogenic addiction'.

"Unlike healthy cells, [oncogenetically addicted] tumour cells show so much plasticity. You hit them at the core, but they still adapt and come up with another solution to survive."

Dr Blancafort, a Spanish cancer geneticist, arrived in WA last year and has since secured research funding from various federal, state and local organisations to move from cell culture studies to safe iPeps use in animal and patient models.

Explore further: Integrin cell adhesion receptors are risky cancer drug targets

Related Stories

Integrin cell adhesion receptors are risky cancer drug targets

February 11, 2014
A possible cancer treatment strategy might in fact lead to increased metastasis in some cases. This finding from a team of LACDR researchers led by Erik Danen made the cover of the February 11 edition of Science Signaling.

Team finds potential cause for deadly breast cancer relapse

November 25, 2013
Researchers at the UNC School of Medicine, working with cell lines in a lab, have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and UNC scientists are developing ways ...

Linking risk factors and disease origins in breast cancer

November 20, 2013
Researchers from the Geisel School of Medicine at Dartmouth have found that epigenetic changes to DNA are associated with aging in disease-free breast tissues and are further altered in breast tumors. Epigenetic changes describe ...

Study reveals unexpected cell hijack method in pancreatic cancer

February 10, 2014
Pancreatic stellate cells, which normally aid tissue repair, unwittingly help pancreatic cancer grow and spread in a method of 'cell hijack' only seen before in brain and breast cancer, according to new research from Queen ...

New finding points to potential options for attacking stem cells in triple-negative breast cancer

February 17, 2014
New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase ...

New drug candidate starves dormant cancer cells

February 18, 2014
In a study published in Nature Communications, researchers at Karolinska Institutet and Uppsala University in Sweden present a new drug candidate, which selectively kills dormant cells within a cancer tumour through starvation. ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.